Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M29.2Revenue $M1.0Net Margin (%)-218.2Z-Score20.4
Enterprise Value $M24.8EPS $-0.0Operating Margin %-220.5F-Score3
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-218.2Higher ROA y-yN
Price/Book5.810-y EBITDA Growth Rate %13.7Quick Ratio7.6Cash flow > EarningsY
Price/Sales46.05-y EBITDA Growth Rate %-15.8Current Ratio7.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-37.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-45.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M63.5ROI % (ttm)-52.3Gross Margin Increase y-yN

Gurus Latest Trades with IGXT

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

IGXT is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


IGXT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Zerbe Horst GDirector 2014-01-31Sell250,000$0.92-50 view
Zerbe IngridCorporate Secretary 2014-01-31Sell250,000$0.92-50 view
BluMont Capital Corp10% Owner 2012-11-09Buy70,000$0.67-31.34 view
BluMont Capital Corp10% Owner 2012-10-11Buy205,000$0.66-30.3 view
BluMont Capital Corp10% Owner 2012-09-19Buy145,000$0.6-23.33 view
BluMont Capital Corp10% Owner 2012-09-07Buy92,000$0.6-23.33 view
BluMont Capital Corp10% Owner 2012-08-15Buy170,000$0.56-17.86 view
BluMont Capital Corp10% Owner 2012-07-11Buy84,345$0.53-13.21 view
BluMont Capital Corp10% Owner 2012-06-18Buy80,000$0.54-14.81 view
BluMont Capital Corp10% Owner 2012-05-10Buy125,000$0.5-8 view

Press Releases about IGXT :

    Quarterly/Annual Reports about IGXT:

      News about IGXT:

      Articles On GuruFocus.com
      No related article found.

      More From Other Websites
      INTELGENX TECHNOLOGIES CORP. Financials Nov 21 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 18 2014
      IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference Nov 18 2014
      10-Q for IntelGenx Technologies Corp. Nov 14 2014
      2014-11-12 IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update Nov 12 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q, Quarterly Report Nov 12 2014
      IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update Nov 12 2014
      Small Cap Traders Delivers Brief Report: IntelGenx Technologies Corporation Targeting Better... Nov 06 2014
      2014-11-03 IntelGenx Announces Successful Clinical Study for Schizophrenia Nov 03 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Nov 03 2014
      IntelGenx Announces Successful Clinical Study for Schizophrenia Nov 03 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Oct 02 2014
      IntelGenx Founder Returns as President and CEO Oct 02 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Oct 01 2014
      IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine... Oct 01 2014
      RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine... Oct 01 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Sep 17 2014
      IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference Sep 17 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Aug 21 2014
      INTELGENX TECHNOLOGIES CORP. Files SEC form 10-Q, Quarterly Report Aug 07 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK